Skip Navigation


NDT Advance Access originally published online on July 13, 2004
Nephrology Dialysis Transplantation 2004 19(9):2272-2274; doi:10.1093/ndt/gfh384
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/9/2272    most recent
gfh384v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kincaid-Smith, P.
Right arrow Articles by Packham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kincaid-Smith, P.
Right arrow Articles by Packham, D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant Vol. 19 No. 9 © ERA-EDTA 2004; all rights reserved


Original Article

Dual blockade of the renin–angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure

Priscilla Kincaid-Smith1,2, Kenneth F. Fairley1 and David Packham1

1 Epworth Hospital, Richmond, Victoria and 2 University of Melbourne, Parkville, Australia

Correspondence and offprint requests to: Priscilla Kincaid-Smith, Epworth Hospital, Richmond, Victoria, Australia. Email: priscillk{at}epworth.org.au

Background. Several publications in the past 2 years have demonstrated that combined angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor antagonist (AIIRA) are more effective in reducing blood pressure and proteinuria in patients with chronic renal disease than ACEI or AIIRA alone. This study compares the effect of increasing the ACEI dose by 50% with that of adding an AIIRA to a standard ACEI dose.

Methods. This study was designed as part of a previous comparison of ACEI with ACEI plus candesartan. Directly after completion of the randomized intervention periods of that study, the dose of ACEI was increased by 50% in all patients. Proteinuria and blood pressure were compared in both groups of patients in the three periods, on standard ACEI, on ACEI plus candesartan and on a dose of ACEI increased by 50%.

Results. No significant differences in the primary end-point proteinuria or secondary end-points were observed when the ACEI dose was increased by 50%. Proteinuria was 1.8 g in 24 h on candesartan and ACEI and 2.4 g in 24 h when the ACEI dose was increased by 50% (P<0.02). Systolic blood pressure was 126.6 mmHg on candesartan and ACEI and 134.47 mmHg when the ACEI dose was increased by 50% (P<0.002). Diastolic blood pressure, serum creatinine, urea and potassium were not different between groups.

Conclusions. Standard ACEI plus candesartan is more effective in reducing systolic blood pressure and proteinuria than a 50% increase in ACEI dose. This has implications for the prevention of renal failure in chronic renal disease.

Keywords: angiotensin-converting enzyme inhibitors; angiotensin-II receptor antagonists; hypertension; proteinuria


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CJASNHome page
Y. Kanno, T. Takenaka, T. Nakamura, and H. Suzuki
Add-On Angiotensin Receptor Blocker in Patients Who Have Proteinuric Chronic Kidney Diseases and Are Treated with Angiotensin-Converting Enzyme Inhibitors
Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 730 - 737.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. Singh
Dual blockade of renin-angiotensin system in primary focal segmental glomerulosclerosis
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 830 - 831.
[Full Text] [PDF]


Home page
CJASNHome page
A. Chrysostomou, E. Pedagogos, L. MacGregor, and G. J. Becker
Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 256 - 262.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.